CRSP (STOCKS)
CRISPR Therapeutics AG
$52.560700
+2.760700 (+5.54%)
Prev close: $49.800000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Samarth Kulkarni
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $5,074.17M
- Employees
- 393
- P/E (TTM)
- -8.02
- P/B (TTM)
- 2.65
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $4.10M |
| Benefits Costs and Expenses | $569.27M |
| Costs And Expenses | $569.27M |
| Nonoperating Income/Loss | $81.23M |
| Operating Expenses | $650.50M |
| Research and Development | $280.90M |
| Other Operating Expenses | $369.60M |
| Operating Income/Loss | -$646.40M |
| Income/Loss From Continuing Operations After Tax | -$568.53M |
| Income/Loss From Continuing Operations Before Tax | -$565.17M |
| Income Tax Expense/Benefit | $3.36M |
| Net Income/Loss | -$568.53M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$568.53M |
| Net Income/Loss Available To Common Stockholders, Basic | -$568.53M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$6.20 |
| Diluted Earnings Per Share | -$6.20 |
| Basic Average Shares | 276,227,123 |
| Diluted Average Shares | 276,227,123 |
| Assets | $2.73B |
| Current Assets | $2.45B |
| Noncurrent Assets | $277.46M |
| Fixed Assets | $112.18M |
| Other Non-current Assets | $165.28M |
| Liabilities | $911.26M |
| Current Liabilities | $136.29M |
| Accounts Payable | $13.65M |
| Wages | $4.84M |
| Other Current Liabilities | $117.80M |
| Noncurrent Liabilities | $774.98M |
| Long-term Debt | $585.47M |
| Other Non-current Liabilities | $189.51M |
| Equity | $1.81B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.81B |
| Liabilities And Equity | $2.73B |
| Net Cash Flow From Operating Activities | -$399.96M |
| Net Cash Flow From Operating Activities, Continuing | -$399.96M |
| Net Cash Flow From Investing Activities | -$422.79M |
| Net Cash Flow From Investing Activities, Continuing | -$422.79M |
| Net Cash Flow From Financing Activities | $1.01B |
| Net Cash Flow From Financing Activities, Continuing | $1.01B |
| Net Cash Flow | $184.59M |
| Net Cash Flow, Continuing | $184.59M |
| Comprehensive Income/Loss | -$574.52M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$574.61M |
| Other Comprehensive Income/Loss | -$112.42M |
| Other Comprehensive Income/Loss Attributable To Parent | -$12.04M |